Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study

Fig. 2

Improvement in disease activity from baseline (unadjusted means (95% CI)) at 3 months by certolizumab pegol level: a ASDAS-CRP improvement in axial spondyloarthritis. b DAS28 improvement in rheumatoid arthritis. c DAS28 improvement in psoriatic arthritis. ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score-C-reactive protein; DAS28, 28-joint Disease Activity Score

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us